Skip to Contents
back
Hanmi pharmaceutical
Hanmi pharmaceutical
Hanmi pharmaceutical
About Us
Hanmi
Founder’s Story
History
Affiliates
Location
ESG
Hanmi ESG
E (Environment)
S (Social)
G (Governance)
ESG Report
Responsibility
CSR
Ethical Management
PR/IR
Press Releases
IR
Stock Information
Financial Information
Science
Science
Science
Hanmi R&D
Research Areas
Technology
Overview
Long-acting platform technology
Bispecific antibody platform technology
Cancer Research
IMD·New Formulation
Pipeline
Pipeline Snapshot
Innovative R&D Pipeline
Focused Pipeline
Business
Business
Business
Open Innovation
CDMO
Product
Contact
Contact
Contact
Contact Us
ENG
open
KOR
ENG
open
KOR
Hanmi pharmaceutical
About Us
Hanmi
Founder’s Story
History
Affiliates
Location
ESG
Hanmi ESG
E (Environment)
S (Social)
G (Governance)
ESG Report
Responsibility
CSR
Ethical Management
PR/IR
Press Releases
IR
Stock Information
Financial Information
Science
Hanmi R&D
Research Areas
Technology
Overview
Long-acting platform technology
Bispecific antibody platform technology
Cancer Research
IMD·New Formulation
Pipeline
Pipeline Snapshot
Innovative R&D Pipeline
Focused Pipeline
Business
Open Innovation
CDMO
Product
Contact
Contact
©Hanmi Pharm.Co.,Ltd. All Rights Reserved.
Hyalrheuma Inj.
Category
Osteoarthritis
Indication
Sodium hyaluronate 10mg / 1mL
Active
Ingredient
Knee osteoarthritis, shoulder osteoarthritis.
Total
2
Press Release from Theva Regarding the U.S. sale of Hanmi Pharmaceutical's Hialuma to Teva.
2019.07.02
Hanmi begins US Phase 3 clinical trial for its osteoarthritis medicine Hyalrheuma
2015.03.31
List
